Table 1 Baseline characteristics
ARNI n = 87 | Standard treatment n = 100 | P-value | |
|---|---|---|---|
Age (mean ± SD) | 63.30 ± 15.03 | 59.14 ± 18.68 | 0.098 |
Male (%) | 59 (67.8) | 61 (61.0) | 0.330 |
BMI (mean ± SD) | 24.9 ± 6.49 | 22.1 ± 7.30 | 0.006 |
Baseline LVEF (mean ± SD) | 26.3 ± 8.38 | 28.50 ± 8.07 | 0.078 |
Baseline SBP (mean ± SD) | 114.3 ± 18.46 | 119.3 ± 19.54 | 0.073 |
Baseline DBP (mean ± SD) | 69.3 ± 9.70 | 71.8 ± 9.91 | 0.085 |
Comorbidities (%) | |||
Hypertension | 52 (59.8) | 46 (46.0) | 0.060 |
Diabetes | 38 (43.7) | 43 (43.0) | 0.926 |
Dyslipidemia | 34 (39.1) | 42 (42.0) | 0.685 |
Coronary artery disease | 35 (40.2) | 41 (41.0) | 0.915 |
Atrial fibrillation | 27 (31.0) | 27 (27.0) | 0.544 |
Mitral regurgitation | 21 (24.1) | 22 (22.0) | 0.729 |
Chronic kidney disease | 16 (18.4) | 32 (32.0) | 0.034 |
Type of cardiomyopathy (%) | |||
Dilated cardiomyopathy | 55 (63.2) | 46 (46.0) | 0.018 |
Ischemic cardiomyopathy | 27 (31.0) | 41 (41.0) | 0.158 |
NYHA classification (%)* | |||
Class I | 12 (13.8) | 22 (22.0) | 0.732 |
Class II | 56 (64.4) | ||
Class III | 9 (10.3) | 10 (10.0) | |
Class IV | 1 (1.2) | 2 (2.0) | |
Intracardiac devices (%) | |||
AICD | 23 (26.4) | 24 (24.0) | 0.702 |
CRT | 23 (26.4) | 13 (13.0) | 0.020 |
Baseline HF medication (%) | |||
Beta-blockers | 81 (93.1) | 92 (92.0) | 0.775 |
MRA | 65 (74.7) | 68 (68.0) | 0.312 |
Ivabradine | 12 (13.8) | 3 (3.0) | 0.007 |
Digoxin | 11 (12.6) | 6 (6.0) | 0.115 |
Diuretics | 59 (67.8) | 72 (72.0) | 0.533 |